E.S. Stepanova; L.M. Makarenkova; S.S. Barsegyan, PhD; V.V. Chistyakov, PhD Peoples’ Friendship University of Russia; 6, Miklukho-Maklai St., Moscow 117198, Russian Federation

Introduction. Angiotensin-converting enzyme inhibitors, perindopril in particular, are used to prevent and treat cardiovascular diseases. To confirm the quality of generic drugs, there is a need for techniques for the simultaneous determination of the active substance itself and its active metabolite perindoprilate. Objective: to develop a simple, reliable, and reproducible technique for simultaneous isolation of perindopril and perindoprilate from plasma and for their quantification using high performance liquid chromatography-mass spectrometry (HPLC-MS). Material and methods. The investigation used the substance perindopril erbumine and the standard perindoprilate and enalapril maleate as an internal standard. The investigation was conducted on a Dionex Ultimate 3000 HPLC with a Bruker micrOTOF-QII mass detector on cartridges for solid-phase extraction (SPE) using an Isolute C18-500 mg column. Chromatograms were processed and a calibration curve was constructed automatically by the Quant Analysis program. Results. A highly selective technique for simultaneous isolation and quantitative determination of perindopril and perindoprilate in plasma, by using SPE on C18 cartridges and HPLC-MS detection, was developed and validated. The total time of chromatographic analysis was 6 min. The lower limits for quantitative determination of perindopril and perindoprilate in plasma are 0.4 and 1.5 ng/ml, respectively. Conclusion. The developed technique is suitable for pharmacokinetic studies and determination of the bioavailability and bioequivalence of perindopril-based drugs

angiotensin-converting enzyme inhibitors
solid-phase extraction
high performance liquid chromatography-mass spectrometry

  1. Cardiovascular diseases (CVDs): Fact sheet [Electron. resource]. World Health Organization. Reviewed June 2016. URL: (date of the application 7.08.2016).
  2. Perindopril: instrukciya, primenenie i formula [E`lektronnyy resurs]. RLS: E`nciklopediya lekarstv i tovarov aptechnogo assortimenta. [Perindopril: instruction, the use and formula [Electron. resource]. Register of medicines: Encyclopedia of medicines and pharmaceutical products range. URL: (date of the application 7.08.2016) (in Russian).
  3. Ramakrishna V.S. Nirogi, Vishwottam N. Kandikere, Manoj Shukla Santosh Maurya, Prashanth Komarneni. High-throughput quantification of perindopril in human plasma by liquid chromatography/tandem mass spectrometry: application to a bioequivalence study. Rapid Commun. Mass Spectrom., 2006; 20: 1864–70.
  4. Deepak S.Jain, Gunta Subbaiah, Mallika Sanyal, Umesh C. Pande, Pranav Shrivastav. First LC–MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study. J. Chromatogr. B, 2006; 837: 92–100.
  5. Georgakakou S., Kazanis M., Panderi I. Hydrophilic interaction liquid chromatography/positive ion electrospray ionization mass spectrometry method for the quantification of perindopril and its main metabolite in human plasma. Anal. Bioanal. Chem., 2010; 397: 2161–70.
  6. Krasnyh L.M., Smirnov V.V., Egorenkov E.A., Vasilenko G.F. Dement`ev S.P., Ramenskaya G.V. Sravnitel`noe izuchenie farmakokinetiki perindoprila i ego metabolita s pomoshh`yu razrabotannogo metoda VE`ZhH/MS. Vedomosti NCE`SMP, 2015; 1: 21–5. [Krasnykh L.M., Smirnov V.V., Egorenkov E.A., Vasilenko G.F., Dement'ev S.P., Ramenskaja G.V. Comparative study of perindopril and perindopril metabolite pharmacokinetics using the HPLC/MS method. Vedomosti NTsESMP, 2015; 1: 21–5] (in Russian).
  7. Guideline on bioanalytical method validation. European medicines agency, 2011.